Search results

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Artificial Intelligence (AI) is reshaping the software landscape, redefining categories and competitive dynamics. Per The Business Research Company, the AI software market is projected to grow to

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to

Kymera Therapeutics KYMR announced that the FDA has granted a Fast Track designation to its lead candidate, KT-621, for the treatment of moderate-to-severe eosinophilic asthma. KYMR shares rose 4%

Johnson & Johnson’s JNJ first-quarter 2026 earnings came in at $2.70 per share, which beat the Zacks Consensus Estimate of $2.67. Earnings declined 2.5% from the year-ago period.

Adjusted earnings

TruBridge (TBRG) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since

Merck MRK and its Japanese partner Daiichi Sankyo announced that the FDA has accepted the biologics license application (BLA) seeking approval for ifinatamab deruxtecan (I-DXd), a B7-H3-directed DXd

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Royalty Pharma

Qualcomm Incorporated QCOM is strengthening its presence in the automotive semiconductor industry by extending its long-standing partnership with Bosch. The deal, which earlier focused on digital

Blue Owl Capital Inc. OWL has spent the past year battling a tough tape for private credit and headline noise around liquidity. Still, the company enters 2026 with a broader growth playbook than

Arista Networks, Inc. ANET plays a critical and rapidly expanding role in the artificial intelligence (AI) ecosystem by providing high-performance networking solutions that power modern AI

Regeneron Pharmaceuticals REGN announced that it has entered into a strategic collaboration with Telix Pharmaceuticals Limited TLX to co-develop and co-commercialize next-generation

Visa Inc. V recently announced a new partnership with Neat to enhance the insurance and medical assistance services embedded within its cards. The collaboration underscores a broader move toward

The Travelers Companies, Inc. TRV has delivered solid financial performance over the past year, supported by consistent revenue growth. In 2025, the company generated approximately $48.8 billion in